Uveitis

MPR Weekly Dose Podcast Episode 98

FDA Advisory Committee votes on whether the Pfizer-BioNTech vaccine should be authorized in 5 to 11 year olds; The Moderna vaccine elicits strong antibody responses in pediatrics; Trial results shed light on booster dose efficacy; Shingrix is recommended for immunocompromised patients; A novel treatment is approved for macular edema associated with uveitis; And Pepaxto is withdrawn following new findings.

New Drug Product: Yutiq

This slideshow reviews drug information for Yutiq. Click here for the complete Yutiq monograph.  For a downloadable PDF of this slideshow, click here.

Yutiq Now Available for Chronic Non-Infectious Posterior Segment Uveitis

EyePoint announced the launch of Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The product was approved by the Food and Drug Administration (FDA) in October 2018.  Yutiq is a sterile non-bioerodible intravitreal implant containing fluocinolone acetonide 0.18mg in a 36-month sustained-release drug delivery system.…